Active8: a randomized, double-blind, placebo-controlled study of chemotherapy plus cetuximab in combination with TLR8 agonist VTX-2337 in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN). (6th November 2014) - Ferris, Robert L; Cohen, Ezra; Gash, Kelly; Whiting, Sam; Manjarrez, Kristi; Dietsch, Greg; Hershberg, Robert; Bryan, James Kyle